Niagen Bioscience (OCD1) Ownership - Who Owns Niagen Bioscience?
Niagen Bioscience (OCD1) Ownership Overview
- 5.07% Insiders
- 7.15% Mutual Funds
- 4.80% Other Institutional Investors
- 8.48% ETFs
- 74.50% Public Companies and Individual Investors
The ownership structure of Niagen Bioscience (DE:OCD1) stock is a mix of institutional, retail, and individual investors. Approximately 20.43% of the company’s stock is owned by Institutional Investors, 5.07% is owned by Insiders, and 74.50% is owned by Public Companies and Individual Investors.
The ownership structure of Niagen Bioscience (DE:OCD1) stock is a mix of institutional, retail, and individual investors. Approximately 20.43% of the company’s stock is owned by Institutional Investors, 5.07% is owned by Insiders, and 74.50% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Nov 16, 2025 | Ozan Pamir | $45,607 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Gamco Investors, Inc. Et Al | €1,023,960 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 4,184,659 | Institution | 5.29% | 8,411,165 |
| Vanguard | 3,124,650 | Institution | 3.95% | 6,280,546 |
| Frank L Jr Jaksch | 2,319,231 | Insider | 2.93% | 4,661,654 |
| Ishares | 2,210,219 | Institution | 2.79% | 4,442,540 |
| Vanguard Index Funds | 2,100,229 | Institution | 2.65% | 4,221,460 |
| Robert Fried | 1,667,834 | Insider | 2.11% | 3,352,346 |
| Fidelity Salem Street Trust | 689,441 | Institution | 0.87% | 1,385,776 |
| Vanguard World Fund | 594,554 | Institution | 0.75% | 1,195,054 |
| Fidelity Concord Street Trust | 525,177 | Institution | 0.66% | 1,055,606 |
| Vanguard Scottsdale Funds | 396,844 | Institution | 0.50% | 797,656 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 2,100,229 | Institution | 2.65% | 4,221,460 |
| Fidelity Salem Street Trust | 689,441 | Institution | 0.87% | 1,385,776 |
| Vanguard World Fund | 594,554 | Institution | 0.75% | 1,195,054 |
| Fidelity Concord Street Trust | 525,177 | Institution | 0.66% | 1,055,606 |
| Vanguard Scottsdale Funds | 396,844 | Institution | 0.50% | 797,656 |
| Victory Portfolios Iii | 305,327 | Institution | 0.39% | 613,707 |
| Vanguard Explorer Fund | 168,651 | Institution | 0.21% | 338,989 |
| Dfa Investment Dimensions Group Inc | 167,355 | Institution | 0.21% | 336,384 |
| Schwab Capital Trust | 165,680 | Institution | 0.21% | 333,017 |
| Tiaa-cref Funds | 120,640 | Institution | 0.15% | 242,486 |
FAQ
Who Owns Niagen Bioscience (DE:OCD1)?
According to the latest TipRanks data, approximately 20.43% of the company's stock is held by institutional investors, 5.07% is held by insiders, and 74.50% is held by public companies and individual investors.
What percentage of Niagen Bioscience (DE:OCD1) stock is held by institutional investors?
According to the latest TipRanks data, approximately 20.43% of Niagen Bioscience (DE:OCD1) stock is held by institutional investors: 7.15% by mutual funds, 8.48% by ETFs and 4.80% by other institutional investors.
What percentage of Niagen Bioscience (DE:OCD1) stock is held by retail investors?
According to the latest TipRanks data, approximately 74.50% of Niagen Bioscience (DE:OCD1) stock is held by public companies and individual investors.
Who owns the most shares of Niagen Bioscience (DE:OCD1)?
BlackRock, Inc. owns the most shares of Niagen Bioscience (DE:OCD1).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
